Gilead Licensing Deal Expands Remdesivir Access, Capacity
Mylan, Cipla, Hetero Labs, Jubilant, Ferozsons Labs Get Rights
Executive Summary
Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.
You may also be interested in...
Coronavirus Update: AZ Gets $1bn From US, Secures Capacity For One Billion Vaccine Doses
Inovio vaccine data published, US government invests to protect, generic remdesivir launched in Bangladesh.
Cipla Propels 'Lung Leadership' Plans
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.
Cipla Propels Lung Leadership Plans, Reimagines Operating Models
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.
Need a specific report? 1000+ reports available
Buy Reports